CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma-Reference-Cited by-同舟云学术

CXC ligand 13 orchestrates an immunoactive microenvironment and enhances immunotherapy response in head and neck squamous cell carcinoma

Published:2024-01 Issue: Volume:38 Page:
ISSN:0394-6320
Container-title:International Journal of Immunopathology and Pharmacology
language:en
Short-container-title:Int J Immunopathol Pharmacol

Author:

Lin Xiaohu¹²³⁴^ORCID,Zhao Xiaomei¹²³⁴,Chen Yiming¹²³⁴,Yang Rong¹²³⁴,Dai Zhenlin¹²³⁴,Li Wei⁵,Lin Chengzhong⁶,Cao Wei¹²³⁴

Affiliation:

1. Department of Oral Maxillofacial-Head and Neck Oncology, Shanghai Ninth People’s Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China

2. College of Stomatology, Shanghai Jiao Tong University, Shanghai, China

3. National Center for Stomatology, National Clinical Research Center for Oral Diseases, Shanghai, China

4. Shanghai Key Laboratory of Stomatology, Shanghai, China

5. Xuchang Central Hospital, Henan, China

6. Department of Oral Maxillofacial Surgery, Zhongshan Hospital, Fu Dan University, Shanghai, China

Abstract

Objectives: This study aims to systematically explore the role of chemokine CXC ligand 13 (CXCL13) in head and neck squamous cell carcinoma (HNSCC). Methods: The Genotype-Tissue Expression (GTEx) and The Cancer Genome Atlas (TCGA) databases provided the RNA-seq data for cancer and normal tissues, respectively. Gene set enrichment analysis was applied to search the cancer hallmarks associated with CXCL13 expression. TIMER2.0 was the main platform used to investigate the immune cell infiltration related to CXCL13. Immunohistochemistry was applied to explore the relationship between CXCL13 and patients’ prognosis and the relationship between CXCL13 and tertiary lymphoid structures (TLSs). Results: The expression of CXCL13 was upregulated in most tumors, including HNSCC. The higher expression of CXCL13 was closely related to the positive prognosis of HNSCC. CXCL13 was mainly expressed in B cells and CD8 + T cells, revealing the relationship between its expression and immune activation in the tumor microenvironment. Furthermore, immunohistochemistry and multiple fluorescence staining analysis of HNSCC samples showed a powerful correlation between CXCL13 expression, TLSs formation, and positive prognosis. Finally, CXCL13 significantly increased the response to cancer immunotherapy. Conclusions: CXCL13 may function as a potential biomarker for predicting prognosis and immunotherapy response and associate with TLSs in HNSCC.

Funder

National Natural Science Foundation of China

Innovation research team of high-level local universities in Shanghai

Publisher

SAGE Publications

Link

http://journals.sagepub.com/doi/pdf/10.1177/03946320241227312

Reference31 articles.

1. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries

2. Head and Neck Squamous Cell Carcinoma in Elderly Patients: Role of Radiotherapy and Chemotherapy

3. Functional Engagement of the PD-1/PD-L1 Complex But Not PD-L1 Expression Is Highly Predictive of Patient Response to Immunotherapy in Non–Small-Cell Lung Cancer

4. Head and Neck Cancer Immunotherapy: Molecular Biological Aspects of Preclinical and Clinical Research

5. Treating Head and Neck Cancer in the Age of Immunotherapy: A 2023 Update